BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37799067)

  • 1. Benefit of living donor liver transplantation in graft survival for extremely high model for end-stage liver disease score ≥35.
    Yun SO; Kim J; Rhu J; Choi GS; Joh JW
    J Hepatobiliary Pancreat Sci; 2023 Dec; 30(12):1293-1303. PubMed ID: 37799067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival benefit of living-donor liver transplantation in patients with a model for end-stage liver disease over 30 in a region with severe organ shortage: a retrospective cohort study.
    Yim SH; Kim DG; Kang M; Koh HH; Choi MC; Min EK; Lee JG; Kim MS; Joo DJ
    Int J Surg; 2023 Nov; 109(11):3459-3466. PubMed ID: 37565633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes in Living Donor Compared With Deceased Donor Primary Liver Transplantation in Lower Acuity Patients With Model for End-Stage Liver Disease Scores <30.
    Kitajima T; Moonka D; Yeddula S; Collins K; Rizzari M; Yoshida A; Abouljoud MS; Nagai S
    Liver Transpl; 2021 Jul; 27(7):971-983. PubMed ID: 33492764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival after live donor versus deceased donor liver transplantation: propensity score-matched study.
    Kaltenmeier C; Liu H; Zhang X; Ganoza A; Crane A; Powers C; Gunabushanam V; Behari J; Molinari M
    BJS Open; 2024 May; 8(3):. PubMed ID: 38837956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable Short- and Long-term Outcomes in Living Donor and Deceased Donor Liver Transplantations for Patients With Model for End-stage Liver Disease Scores ≥35 in a Hepatitis-B Endemic Area.
    Chok KS; Fung JY; Chan AC; Dai WC; Sharr WW; Cheung TT; Chan SC; Lo CM
    Ann Surg; 2017 Jan; 265(1):173-177. PubMed ID: 28009743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
    Gordon FD; Goldberg DS; Goodrich NP; Lok AS; Verna EC; Selzner N; Stravitz RT; Merion RM
    Liver Transpl; 2016 Sep; 22(9):1214-22. PubMed ID: 27339253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of rates and severity of chronic kidney disease in deceased-donor and living-donor liver transplant recipients: times matter.
    Yankol Y; Bugeaud E; Zens T; Rizzari M; Mecit N; Leverson GE; Foley D; Mezrich JD; Kanmaz T; Andaçoğlu OM; D'Alessandro AM; Acarlı KS; Kalayoğlu M; Fernandez LA
    Turk J Med Sci; 2021 Apr; 51(2):610-622. PubMed ID: 33037873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
    Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
    Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Living donor liver transplant versus cadaveric liver transplant survival in relation to model for end-stage liver disease score.
    Al Sebayel M; Abaalkhail F; Hashim A; Al Bahili H; Alabbad S; Shoukdy M; Elsiesy H
    Transplant Proc; 2015 May; 47(4):1211-3. PubMed ID: 26036556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Living donor versus deceased donor liver transplantation: a surgeon-matched comparison of recipient morbidity and outcomes.
    Reichman TW; Katchman H; Tanaka T; Greig PD; McGilvray ID; Cattral MS; Renner EL; Selzner M; Ghanekar A; Levy G; Grant DR
    Transpl Int; 2013 Aug; 26(8):780-7. PubMed ID: 23746118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing practice and acceptable outcomes of high-MELD living donor liver transplantation in the USA.
    Anouti A; Patel MS; VanWagner LB; Lee WM; Asrani SK; Mufti AR; Rich NE; Vagefi PA; Shah JA; Kerr TA; Pedersen M; Hanish S; Singal AG; Cotter TG
    Liver Transpl; 2024 Jan; 30(1):72-82. PubMed ID: 37490432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.
    Terrault NA; Shiffman ML; Lok AS; Saab S; Tong L; Brown RS; Everson GT; Reddy KR; Fair JH; Kulik LM; Pruett TL; Seeff LB;
    Liver Transpl; 2007 Jan; 13(1):122-9. PubMed ID: 17192908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up.
    Jain A; Singhal A; Kashyap R; Safadjou S; Ryan CK; Orloff MS
    Transplantation; 2011 Aug; 92(4):453-60. PubMed ID: 21799468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes of right-lobe living donor liver transplantation for patients with high Model for End-stage Liver Disease scores.
    Chok KSh; Chan SC; Fung JY; Cheung TT; Chan AC; Fan ST; Lo CM
    Hepatobiliary Pancreat Dis Int; 2013 Jun; 12(3):256-62. PubMed ID: 23742770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult-to-adult right-lobe living donor liver transplantation in recipients with hepatitis B virus-related benign liver disease and high model end-stage liver disease scores.
    Jiang L; Yan L; Tan Y; Li B; Wen T; Yang J; Zhao J
    Surg Today; 2013 Sep; 43(9):1039-48. PubMed ID: 23467980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Risk of End-Stage Renal Disease Among Living Donor Liver Transplant Recipients in the United States.
    Goldberg DS; Ruebner RL; Abt PL
    Am J Transplant; 2015 Oct; 15(10):2732-8. PubMed ID: 25969133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Living Donation Versus Donation After Circulatory Death Liver Transplantation for Low Model for End-Stage Liver Disease Recipients.
    Kling CE; Perkins JD; Reyes JD; Montenovo MI
    Liver Transpl; 2019 Apr; 25(4):580-587. PubMed ID: 29637730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of pediatric living donor compared to deceased donor liver transplantation in the PELD/MELD era: Experience from two centers on two different continents.
    Yankol Y; Fernandez LA; Kanmaz T; Leverson GE; Mezrich JD; Foley D; Mecit N; D'Alessandro AM; Acarli K; Kalayoglu M
    Pediatr Transplant; 2016 Feb; 20(1):72-82. PubMed ID: 26861217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison.
    Wan P; Zhang JJ; Li QG; Xu N; Zhang M; Chen XS; Han LZ; Xia Q
    World J Gastroenterol; 2014 Apr; 20(15):4393-400. PubMed ID: 24764678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
    Hayashi PH; Forman L; Steinberg T; Bak T; Wachs M; Kugelmas M; Everson GT; Kam I; Trotter JF
    Liver Transpl; 2003 Jul; 9(7):737-40. PubMed ID: 12827562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.